Support for all stages of drug discovery, development, and commercialization programs will be provided.
SAFC’s pharma business segment opened a medicinal chemistry facility in Bangalore, India. The 139,000-sq-ft facility represents a $12-million investment and is considered a continuation of SAFC’s “build or acquire” strategy, put in place to meet the increased demands for its medicinal chemistry and cGMP manufacturing services.

SAFC Bangalore features over 60,000 sq. ft. of production and R&D laboratory space, including manufacturing suites for chemical development and production to 50-L scale and an on-site warehouse.

The operation offers a range of preclinical, process development, and scale-up services. Procedures are in place to work in alignment with SAFC’s Manchester, U.K., medicinal chemistry operations, ensure intellectual property protection, and to provide seamless technology transfer to SAFC manufacturing facilities worldwide.

Previous articleXenomics Isolates Cell-Free Nucleic Acids From Urine
Next articleGenVec Could Receive $52-M to Support HIV Vaccine Production